Literature DB >> 22271475

Design issues in randomized phase II/III trials.

Edward L Korn1, Boris Freidlin, Jeffrey S Abrams, Susan Halabi.   

Abstract

Phase II trials are used to show sufficient preliminary activity of a new treatment (in single-arm designs or randomized screening designs) or to select among treatments with demonstrated activity (in randomized selection designs). The treatments prioritized in a phase II trial are then tested definitively against a control treatment in a randomized phase III trial. Randomized phase II/III trials use an adaptive trial design that combines these two types of trials in one, with potential gains in time and reduced numbers of patients required to be treated. Two key considerations in designing a phase II/III trial are whether to suspend accrual while the phase II data mature and the choice of phase II target treatment effect. We discuss these phase II/III design parameters, give examples of phase II/III trials, and provide recommendations concerning efficient phase II/III trial designs.

Entities:  

Mesh:

Year:  2012        PMID: 22271475      PMCID: PMC3295562          DOI: 10.1200/JCO.2011.38.5732

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  19 in total

1.  Design issues of randomized phase II trials and a proposal for phase II screening trials.

Authors:  Lawrence V Rubinstein; Edward L Korn; Boris Freidlin; Sally Hunsberger; S Percy Ivy; Malcolm A Smith
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

2.  Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.

Authors:  Frank Bretz; Heinz Schmidli; Franz König; Amy Racine; Willi Maurer
Journal:  Biom J       Date:  2006-08       Impact factor: 2.207

3.  Interim futility analysis with intermediate endpoints.

Authors:  Bryan Goldman; Michael LeBlanc; John Crowley
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

4.  Monitoring for lack of benefit: a critical component of a randomized clinical trial.

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

Review 5.  Multi-arm clinical trials of new agents: some design considerations.

Authors:  Boris Freidlin; Edward L Korn; Robert Gray; Alison Martin
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

6.  Optimal two-stage designs for phase II clinical trials.

Authors:  R Simon
Journal:  Control Clin Trials       Date:  1989-03

7.  Randomized phase II clinical trials.

Authors:  R Simon; R E Wittes; S S Ellenberg
Journal:  Cancer Treat Rep       Date:  1985-12

Review 8.  Clinical trial designs for cytostatic agents: are new approaches needed?

Authors:  E L Korn; S G Arbuck; J M Pluda; R Simon; R S Kaplan; M C Christian
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

9.  Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.

Authors:  Edward L Korn; Ping-Yu Liu; Sandra J Lee; Judith-Anne W Chapman; Donna Niedzwiecki; Vera J Suman; James Moon; Vernon K Sondak; Michael B Atkins; Elizabeth A Eisenhauer; Wendy Parulekar; Svetomir N Markovic; Scott Saxman; John M Kirkwood
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

10.  Speeding up the evaluation of new agents in cancer.

Authors:  Mahesh K B Parmar; Friederike M-S Barthel; Matthew Sydes; Ruth Langley; Rick Kaplan; Elizabeth Eisenhauer; Mark Brady; Nicholas James; Michael A Bookman; Ann-Marie Swart; Wendi Qian; Patrick Royston
Journal:  J Natl Cancer Inst       Date:  2008-08-26       Impact factor: 13.506

View more
  26 in total

1.  Design Issues in Randomized Clinical Trials of Maintenance Therapies.

Authors:  Boris Freidlin; Richard F Little; Edward L Korn
Journal:  J Natl Cancer Inst       Date:  2015-08-18       Impact factor: 13.506

2.  Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation.

Authors:  Steven J Frank; Pierre Blanchard; J Jack Lee; Erich M Sturgis; Merrill S Kies; Mitchell Machtay; Bhadrasain Vikram; Adam S Garden; David I Rosenthal; G Brandon Gunn; C David Fuller; Katherine Hutcheson; Stephen Lai; Paul M Busse; Nancy Y Lee; Alexander Lin; Robert L Foote
Journal:  Semin Radiat Oncol       Date:  2018-04       Impact factor: 5.934

3.  Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements.

Authors:  Edward L Korn; Boris Freidlin
Journal:  J Natl Cancer Inst       Date:  2017-06-01       Impact factor: 13.506

4.  Randomized phase II trial designs with biomarkers.

Authors:  Boris Freidlin; Lisa M McShane; Mei-Yin C Polley; Edward L Korn
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

5.  Decade in review--clinical trials: shifting paradigms in cancer clinical trial design.

Authors:  Daniel J Sargent; Edward L Korn
Journal:  Nat Rev Clin Oncol       Date:  2014-10-07       Impact factor: 66.675

Review 6.  Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations.

Authors:  Chen Hu; James J Dignam
Journal:  JCO Precis Oncol       Date:  2019-10-24

7.  Bias, Operational Bias, and Generalizability in Phase II/III Trials.

Authors:  Boris Freidlin; Edward L Korn; Jeffrey S Abrams
Journal:  J Clin Oncol       Date:  2018-04-26       Impact factor: 44.544

8.  Advances in Statistical Approaches Oncology Drug Development.

Authors:  Anastasia Ivanova; Gary L Rosner; Olga Marchenko; Tom Parke; Inna Perevozskaya; Yanping Wang
Journal:  Ther Innov Regul Sci       Date:  2014-01       Impact factor: 1.778

9.  Response adaptive randomization procedures in seamless phase II/III clinical trials.

Authors:  Hongjian Zhu; Jin Piao; J Jack Lee; Feifang Hu; Lixin Zhang
Journal:  J Biopharm Stat       Date:  2019-08-27       Impact factor: 1.051

Review 10.  Clinical trials in gynecologic oncology: Past, present, and future.

Authors:  Christina M Annunziata; Elise C Kohn
Journal:  Gynecol Oncol       Date:  2017-12-06       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.